186 related articles for article (PubMed ID: 23665950)
41. Phase I clinical trial of oral administration of S-1 in combination with intravenous gemcitabine and cisplatin in patients with advanced biliary tract cancer.
Shoji H; Morizane C; Sakamoto Y; Kondo S; Ueno H; Takahashi H; Ohno I; Shimizu S; Mitsunaga S; Ikeda M; Okusaka T
Jpn J Clin Oncol; 2016 Feb; 46(2):132-7. PubMed ID: 26685318
[TBL] [Abstract][Full Text] [Related]
42. A phase I/II study of S-1 plus cisplatin in patients with advanced gastric cancer: 2-week S-1 administration regimen.
Sato Y; Kondo H; Honda K; Takahari D; Sumiyoshi T; Tsuji Y; Yoshizaki N; Niitsu Y
Int J Clin Oncol; 2005 Feb; 10(1):40-4. PubMed ID: 15729600
[TBL] [Abstract][Full Text] [Related]
43. Phase I/II and pharmacokinetic study of S-1 and oxaliplatin in previously untreated advanced gastric cancer.
Park I; Lee JL; Ryu MH; Chang HM; Kim TW; Sym SJ; Lee SS; Jang G; Yoo C; Bae KS; Kang YK
Cancer Chemother Pharmacol; 2010 Feb; 65(3):473-80. PubMed ID: 19551382
[TBL] [Abstract][Full Text] [Related]
44. Phase I and pharmacokinetic study of the oral fluoropyrimidine S-1 on a once-daily-for-28-day schedule in patients with advanced malignancies.
Chu QS; Hammond LA; Schwartz G; Ochoa L; Rha SY; Denis L; Molpus K; Roedig B; Letrent SP; Damle B; DeCillis AP; Rowinsky EK
Clin Cancer Res; 2004 Aug; 10(15):4913-21. PubMed ID: 15297391
[TBL] [Abstract][Full Text] [Related]
45. Phase I study on the safety, pharmacokinetic profile, and efficacy of the combination of TSU-68, an oral antiangiogenic agent, and S-1 in patients with advanced hepatocellular carcinoma.
Ikeda M; Shiina S; Nakachi K; Mitsunaga S; Shimizu S; Kojima Y; Ueno H; Morizane C; Kondo S; Sakamoto Y; Asaoka Y; Tateishi R; Koike K; Arioka H; Okusaka T
Invest New Drugs; 2014 Oct; 32(5):928-36. PubMed ID: 24829073
[TBL] [Abstract][Full Text] [Related]
46. A phase II study of biweekly oxaliplatin plus S-1 combination chemotherapy as a first-line treatment for patients with metastatic or advanced gastric cancer in China.
Xiao C; Qian J; Zheng Y; Song F; Wang Q; Jiang H; Mao C; Xu N
Medicine (Baltimore); 2019 May; 98(20):e15696. PubMed ID: 31096513
[TBL] [Abstract][Full Text] [Related]
47. A phase II study of biweekly S-1 and paclitaxel (SPA) as first-line chemotherapy in patients with metastatic or advanced gastric cancer.
Jiang H; Qian J; Zhao P; Zhang X; Zheng Y; Mao C; Zheng Y; Chen L; Wang Y; Mou H; Fang W; Teng L; Xu N
Cancer Chemother Pharmacol; 2015 Jul; 76(1):197-203. PubMed ID: 26013324
[TBL] [Abstract][Full Text] [Related]
48. A phase I, dose-finding study of sunitinib in combination with irinotecan in patients with advanced solid tumours.
Boven E; Massard C; Armand JP; Tillier C; Hartog V; Brega NM; Countouriotis AM; Ruiz-Garcia A; Soria JC
Br J Cancer; 2010 Sep; 103(7):993-1000. PubMed ID: 20717111
[TBL] [Abstract][Full Text] [Related]
49. Safety, pharmacokinetic, and clinical activity profiles of ramucirumab in combination with three platinum/fluoropyrimidine doublets in Japanese patients with chemotherapy-naïve metastatic gastric/gastroesophageal junction cancer.
Shitara K; Kadowaki S; Nishina T; Sakai D; Yoshikawa R; Piao Y; Ozeki A; Inoue K; Gritli I; Muro K
Gastric Cancer; 2018 Jan; 21(1):106-113. PubMed ID: 28667466
[TBL] [Abstract][Full Text] [Related]
50. Phase I study of oral S-1 plus Cisplatin with concurrent radiotherapy for locally advanced non-small-cell lung cancer.
Kaira K; Sunaga N; Yanagitani N; Kawata T; Utsugi M; Shimizu K; Ebara T; Kawamura H; Nonaka T; Ishikawa H; Sakurai H; Suga T; Hara K; Hisada T; Ishizuka T; Nakano T; Mori M
Int J Radiat Oncol Biol Phys; 2009 Sep; 75(1):109-14. PubMed ID: 18929446
[TBL] [Abstract][Full Text] [Related]
51. Combination chemotherapy of S-1 and low-dose cisplatin for advanced gastric cancer.
Tsujitani S; Fukuda K; Kaibara N
Gastric Cancer; 2003; 6 Suppl 1():50-7. PubMed ID: 12775021
[TBL] [Abstract][Full Text] [Related]
52. A phase II multicentric trial of S-1 combined with 24 h-infusion of cisplatin in patients with advanced gastric cancer.
Iwase H; Shimada M; Tsuzuki T; Horiuchi Y; Kumada S; Haruta J; Yamaguchi T; Sugihara M; Ina K; Kusugami K; Goto S
Anticancer Res; 2005; 25(2B):1297-301. PubMed ID: 15865081
[TBL] [Abstract][Full Text] [Related]
53. Three-weekly S-1 plus cisplatin chemotherapy as first-line treatment for advanced gastric cancer.
Choi IS; Lee KW; Kim KH; Kim YJ; Kim JH; Lee JS
Med Oncol; 2010 Sep; 27(3):992-7. PubMed ID: 20077040
[TBL] [Abstract][Full Text] [Related]
54. A multicenter phase II study of combined chemotherapy with docetaxel, cisplatin, and S-1 in patients with unresectable or recurrent gastric cancer (KDOG 0601).
Koizumi W; Nakayama N; Tanabe S; Sasaki T; Higuchi K; Nishimura K; Takagi S; Azuma M; Ae T; Ishido K; Nakatani K; Naruke A; Katada C
Cancer Chemother Pharmacol; 2012 Feb; 69(2):407-13. PubMed ID: 21796483
[TBL] [Abstract][Full Text] [Related]
55. Feasibility study of two schedules of sunitinib in combination with pemetrexed in patients with advanced solid tumors.
Okamoto I; Shimizu T; Miyazaki M; Tsurutani J; Ichikawa Y; Terashima M; Takeda M; Fumita S; Ohki E; Kimura N; Hashimoto J; Nakagawa K
Invest New Drugs; 2012 Apr; 30(2):639-46. PubMed ID: 20960028
[TBL] [Abstract][Full Text] [Related]
56. Phase I study of sunitinib in combination with gemcitabine and capecitabine for first-line treatment of metastatic or unresectable renal cell carcinoma.
Bellmunt J; Suarez C; Gallardo E; Rodon J; Pons F; Bonfill T; Beltran M; Moya I; Galtes S; Albanell J; Carles J
Oncologist; 2014 Sep; 19(9):917-8. PubMed ID: 25142843
[TBL] [Abstract][Full Text] [Related]
57. A multicenter, phase I dose-escalating study of docetaxel, cisplatin and S-1 for advanced gastric cancer (KDOG0601).
Nakayama N; Koizumi W; Sasaki T; Higuchi K; Tanabe S; Nishimura K; Katada C; Nakatani K; Takagi S; Saigenji K
Oncology; 2008; 75(1-2):1-7. PubMed ID: 18719348
[TBL] [Abstract][Full Text] [Related]
58. Phase 1 dose-escalation trial of tremelimumab plus sunitinib in patients with metastatic renal cell carcinoma.
Rini BI; Stein M; Shannon P; Eddy S; Tyler A; Stephenson JJ; Catlett L; Huang B; Healey D; Gordon M
Cancer; 2011 Feb; 117(4):758-67. PubMed ID: 20922784
[TBL] [Abstract][Full Text] [Related]
59. Phase I study of S-1 combined with irinotecan (CPT-11) in patients with advanced gastric cancer (OGSG 0002).
Takiuchi H; Narahara H; Tsujinaka T; Gotoh M; Kawabe S; Katsu K; Iishi H; Tatsuta M; Fujitani K; Furukawa H; Taguchi T;
Jpn J Clin Oncol; 2005 Sep; 35(9):520-5. PubMed ID: 16141295
[TBL] [Abstract][Full Text] [Related]
60. Phase I and pharmacokinetic study of S-1 combined with weekly paclitaxel in patients with advanced gastric cancer.
Fujitani K; Narahara H; Takiuchi H; Tsujinaka T; Satomi E; Gotoh M; Hirao M; Furukawa H; Taguchi T
Oncology; 2005; 69(5):414-20. PubMed ID: 16319513
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]